Agricultural damage is common in armed conflict, and has been documented with satellite analysis in Ukraine since the 2022 ...

A combination of homegrown capabilities and significant acquisitions has made Cognizant a key player in bringing AI to ...

Wall Street analysts expect Gilead Sciences (GILD) to post quarterly earnings of $1.66 per share in its upcoming report, which indicates a year-over-year decline of 3.5%. Revenues are expected to be ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

$2,440,000 of GILEAD SCIENCES INC lobbying was just disclosed, from Q4 of 2024, in a new Lobbying Disclosure Act filing. This included lobbying on issues like: "International trade and protection ...

Biotech giant Gilead Sciences, Inc. GILD has put up a strong performance amid a volatile market. Shares of this biotech giant have gained 26.8% in the past six months against the industry’s ...

Gilead Sciences’ Livdelzi (seladelpar) has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) to treat adults with the rare liver disease primary biliary cholangitis (PBC) ...

Gilead Sciences Inc. and the federal government settled a patent-infringement case in which the US sought $1 billion from the bioscience giant for allegedly using joint research to develop an ...

After a run of court victories in a five-year patent dispute with the U.S. government, Gilead Sciences has agreed to settle with the Department of Justice (DOJ) and the Department of Health and ...

Brian Heath has joined Gilead Sciences’ cell therapy subsidiary as a senior vice president and head of global commercial, he announced on LinkedIn this week. “CAR T-cell therapy has changed ...